Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.9 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 2.57% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (up 2.57% YoY), while the FY2025 annual figure was $3.9 billion, up 8.32% from the prior year.
• Total Current Liabilities was $3.9 billion for Q1 2026 at Vertex Pharmaceuticals, up from $3.9 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $4.5 billion in Q3 2025 to a low of $2.2 billion in Q1 2022.
• Historically, Total Current Liabilities has averaged $3.4 billion across 5 years, with a median of $3.6 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities soared 39.19% in 2022, then dropped 0.33% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $2.7 billion in 2022, then increased by 29.37% to $3.5 billion in 2023, then increased by 0.48% to $3.6 billion in 2024, then grew by 8.32% to $3.9 billion in 2025, then advanced by 0.5% to $3.9 billion in 2026.
• The last three Total Current Liabilities figures came in at $3.9 billion (Q1 2026), $3.9 billion (Q4 2025), and $4.5 billion (Q3 2025), per Business Quant data.